| Name | Title | Contact Details |
|---|
American Red Cross - St. Paul Area is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Possis Medical, Inc. is a developer, manufacturer and marketer of medical devices, operating in one business segment.
At Longmont United Hospital we are committed to providing compassionate health care in a healing environment and to providing leadership to improve the health of the community we serve. We are a full-service, 201-bed, non-profit hospital. Our specialty areas include Women’s Services, Orthopedics, Cardiology, Oncology, Robotic Surgery, Transitional Care and Acute Medical Services. Our 24-hour Emergency Department is a Level III Trauma Center. Longmont United Hospital is a Planetree Patient-Centered Care Designated hospital in Northern Colorado. We have served the people of Longmont, CO for over 59 years.
SVHC is a faith-based, not-for-profit health system that has served the people of Jacksonville and the surrounding communities since 1916
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.